| Literature DB >> 31468273 |
Eleanor M Eckert1, Kelli C Dominick2,3, Ernest V Pedapati2,3, Logan K Wink2,3, Rebecca C Shaffer4,5, Howard Andrews6, Tse-Hwei Choo7, Chen Chen7, Walter E Kaufmann8,9, Nicole Tartaglia10, Elizabeth M Berry-Kravis11, Craig A Erickson12,13,14.
Abstract
Using a dataset involving 415 individuals with irritability, aggression, agitation and self-injury (IAAS) behaviors from the fragile X syndrome (FXS) FORWARD database, we describe the psychopharmacologic management of IAAS and features of the population of persons with FXS treated with drug therapy for IAAS. Among those with FXS exhibiting IAAS, individuals with FXS receiving drug treatment of IAAS were older, more predominantly male, have more significant intellectual disability, more like to have comorbid autism, hyperarousal, and social impairments. The most commonly utilized medications for IAAS in FXS are antipsychotic medications, specifically aripiprazole and risperidone (37% and 27%, respectively). The majority of subjects (63%) experienced no side effects noted from the use of their psychopharmacologic medications.Entities:
Keywords: Fragile X syndrome; Irritability; Pharmacotherapy
Mesh:
Substances:
Year: 2019 PMID: 31468273 PMCID: PMC8211361 DOI: 10.1007/s10803-019-04173-z
Source DB: PubMed Journal: J Autism Dev Disord ISSN: 0162-3257